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Key Points
• Epigenetic therapy after
allo-HSCT with panobi-
nostat alone and in
combination with low-
dose decitabine is fea-
sible in poor-risk AML.
• Results did not suggest
a synergistic or additive
effect of combining
panobinostat with
decitabine.
Outcome after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is adversely
affected by relapse to a considerable degree. To exploit the graft-versus-leukemia effect
more effectively, we assessed the feasibility of early initiation of epigenetic therapy with
panobinostat and decitabine after allo-HSCT and before donor lymphocyte infusion (DLI) in
poor-risk patients with acute myeloid leukemia (AML) or refractory anemia with excess
blasts with International Prognostic Scoring System score $1.5. A total of 140 poor-risk
patients with AML aged 18 to 70 years were registered, and 110 proceeded to allo-HSCT.
Three dose levels were evaluated for dose-limiting toxicities, including panobinostat
monotherapy 20 mg at days 1, 4, 8, and 11 of a 4-week cycle (PNB mono group) and
panobinostat combined with either decitabine 20 mg/m2 (PNB/DAC20 group) or decitabine
10 mg/m2 (PNB/DAC10 group) at days 1 to 3 of every 4-week cycle. After phase 1, the
study continued as phase 2, focusing on completion of protocol treatment and treatment
outcome. PNB mono and PNB/DAC10 were feasible, whereas PNB/DAC20 was not related
to prolonged cytopenia. Sixty of 110 patients who underwent transplantation were eligible
to receive their first DLI within 115 days after allo-HSCT. Grade 3 and 4 adverse events
related to panobinostat and decitabine were observed in 23 (26%) of the 87 patients, and
they received epigenetic therapy. Cumulative incidence of relapse was 35% (standard error
[SE] 5), and overall survival and progression-free survival at 24 months were 50% (SE 5)
and 49% (SE 5). Post–allo-HSCT epigenetic therapy with panobinostat alone or in
combination with low-dose decitabine is feasible and is associated with a relatively low
relapse rate. The trial was registered at the European Clinical Trial Registry, https://www.
clinicaltrialsregister.eu, as ECT2012-003344-74.
Introduction
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the preferred treatment to consolidate
remission in (very) poor-risk patients with acute myeloid leukemia (AML).1-3 The graft-versus-leukemia
(GVL) effect of allo-HSCT reduces relapse in a similar, relative degree in all subcategories of AML.4,5
Despite the presence of a strong GVL effect, the absolute incidence of relapse in poor-risk patients with
AML remains considerable.1 To optimize the immunotherapeutic effect of GVL, several phase 1 and 2
trials were conducted to explore the use of hypomethylating agents after allo-HSCT, with the goal of
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restoring epigenetic deregulation of residual leukemic cells and
enhancing allogeneic immunotherapy.6-11 In addition, the feasibility
of the histone deacetylation inhibitor panobinostat when given after
allo-HSCT has been shown.12 Combining hypomethylating drugs
with a histone deacetylation inhibitor has been investigated in
vitro13-16 and in vivo17-19 and may exert additive or synergistic effects;
however, the feasibility and efficacy of their combination in patients
with AML is currently unknown. In this multicenter phase 1/2 Dutch-
Belgian Haemato-Oncology Foundation for Adults (HOVON) trial, we
addressed the feasibility of early epigenetic therapy by panobinostat
alone and in combination with decitabine before donor lymphocyte
infusion (DLI) in recipients of allo-HSCT.
Methods
Patient selection and materials
All patients with AML were registered after diagnosis and classi-
fication as poor risk, before the start of the second cycle of
induction chemotherapy. The study was open for patient accrual
from November 2013 through August 2017. Poor- and very-poor-
risk patients aged 18 to 70 years who had a diagnosis of AML or
refractory anemia with excess blasts with International Prognos-
tic Scoring System score $1.5, according to the latest (2015)
HOVON-AML risk classification, were eligible (supplemental Ap-
pendix, details of the HOVON 116 study, section 1), if the intention
was to perform allo-HSCT as consolidation therapy after 2 cycles
of chemotherapy. A donor search started immediately after the
patient was registered, with the purpose of performing a trans-
plantation within 6 to 8 weeks after the second cycle of induction
chemotherapy with either a matched sibling or a matched unrelated
donor. At the time of allo-HSCT, patients had to fulfill a second set
of eligibility criteria, including disease response (,10% blasts at
3 and/or 4 weeks after the start of cycle 2) and HLA-compatible
donor availability ($7 of 8 HLA-matched unrelated donor or fully
matched sibling donor). A detailed description of the inclusion and
exclusion criteria of the study are presented in the supplemental
Appendix (details of the HOVON 116 study, sections 2 and 3).
Minimal residual disease (MRD) was assessed in bone marrow
samples, and flow cytometry analysis was performed in a 2-step
procedure, as previously described.20,21 MRD samples were obtained
after cycle 2 and before allo-HSCT. The trial was approved by
the ethics committees of the participating institutions and was
conducted in accordance with the Declaration of Helsinki. All
participants gave written informed consent.
Study design
The study was designed as a prospective multicenter phase 1/2
feasibility study. Patients were registered during induction chemo-
therapy for newly diagnosed AML or myelodysplasia syndrome.
Subsequently, they were required to fulfill a second set of eligibility
criteria just before allo-HSCT. The study started as a phase 1 study
exploring 3 dose levels in 29 patients (part 1). After the feasibility of
2 of the 3 dose levels was demonstrated, the study continued as
a phase 2 feasibility study focusing on treatment outcome
parameters and completion of the protocol treatment (part 2).
Part 1. In the first part of the study, the feasibility of epigenetic
combination therapy was assessed. Only very-poor-risk patients
with AML were included in this part of the study. Dose levels
consisted of panobinostat monotherapy (20 mg) alone at days 1, 4,
8, and 11 of a 4-week cycle (PNB mono) and in combination with
decitabine (PNB/DAC20) at a dose of 20 or 10 mg/m2 at days 1 to
3 of every 4-week cycle (PNB/DAC10). PNB mono and PNB/
DAC10 appeared feasible, and those treatment groups therefore
included more patients to address the questions in part 2 of
the study.
The primary end point of part 1 was feasibility, as defined by the
number of dose-limiting toxicities (DLTs) during the first cycle of
epigenetic therapy (,4 of 10 patients). DLTs included grade 4
nonhematological toxicity, treatment-related mortality, and hemato-
logical toxicity between cycles 1 and 2 of epigenetic therapy, which
resulted in delay of the start of cycle 2 after day 35 because of the
transplantation (supplemental Figure 1; supplemental Appendix,
details of the HOVON 116 study, section 5).
Part 2. Part 2 of the study continued with inclusion of patients in
the feasible dose levels of the PNB mono and PNB/DAC10 groups.
This part of the study focused on the completion of protocol
treatment within the defined time frame of 115 days up to the first
DLI, without the occurrence of adverse events (AEs) and/or acute
graft-versus-host disease (GVHD). The inclusion and exclusion
criteria for patients to continue with epigenetic therapy are noted in
the supplemental Appendix (details of the HOVON 116 study,
section 4). AEs were graded using the Common Terminology
Criteria for Adverse Events, version 4.0.22 Acute and chronic GVHD
was defined according to the latest proposal of the recent National
Institutes of Health Consensus Conference.23 Phase 2 of the study
was performed as a Simon-2 stage design for DLT-feasible dose
levels separately, including interim analyses. Secondary end points
included survival analyses consisting of overall survival (OS) from
the date of allo-HSCT, cumulative incidence of relapse (CIR),
nonrelapse mortality (NRM), and progression-free survival (PFS)
from the date of allo-HSCT.
Treatment protocol
The treatment protocol is summarized in Figure 1. All patients
received 2 cycles of induction chemotherapy, regardless of
response to cycle 1. Patients received idarubicin 12 mg/m2
at days 1 to 3 and cytarabine 200 mg/m2 at days 1 to 7 in cycle
1, followed by daunorubicin 60 mg/m2 at days 1, 3, and 5 and
1000 mg/m2 at days 1 to 6 in cycle 2. T-cell–replete allogeneic
transplantation was performed after conditioning with intravenous
cyclophosphamide 14.5 mg/kg per day at days 26 and 25,
fludarabine 30 mg/m2 per day at days 26 to 22, and 2-Gy total
body radiation at day 21. At days 13 and 14, cyclophosphamide
(50 mg/kg per day IV) was given for prevention of GVHD and to
allow for early initiation of epigenetic therapy, followed by 3 mg/kg
per day cyclosporine at days 15 to 170, based on through levels.
Patients were assigned to 4 cycles of epigenetic therapy,
interspersed with the first DLI at day 190 to 1100 and the second
one at day 1180 to 1200 after allo-HSCT. Cyclosporine was
discontinued before the first DLI. The first cycle started at day 28
after allo-HSCT or as soon as possible thereafter, when the patient
met the criteria (supplemental Appendix, details of the HOVON 116
study, section 4). After the first DLI, patients received cycle 3 and 4
of epigenetic therapy. Cycle 3 started at day 21 after DLI, and cycle
4 was given at day 49, or as soon as possible after hematological
recovery.
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Statistical methods
OS, CIR, NRM, and PFS were analyzed using actuarial estimates
and the Kaplan-Meier method. The event for OS consisted of death
from any cause, and the patients were censored at the date of last
contact. The events for PFS were death in remission and relapse.
The cumulative risks of relapse and NRM over time were calculated
as competing risks with actuarial methods, whereas patients alive
and continuing in complete response 1 (CR1) were censored at the
date of last contact. The starting point of all survival curves is the
date of transplantation, if not stated otherwise. All P values were
based on log-rank tests.
Results
Patient and transplant characteristics
A total of 140 (very) poor-risk patients with AML were registered in
this study during induction chemotherapy for AML or myelodys-
plasia syndrome; 110 patients underwent an allo-HSCT according
to protocol, with either a matched sibling or a matched unrelated
donor. The diagnosis of poor-prognosis AML was revised in 1
patient after registration. As a result, this patient was removed from
all additional analyses. The reason for exclusion of the remaining 29
patients included refractory AML (n 5 8), no sibling or unrelated
donor available (n 5 7), refusal (n 5 4), death (n 5 3), and other
(n 5 7). Patient characteristics are presented in Table 1. Median
age at diagnosis was 59 years (range, 18-71). World Health
Organization (WHO) performance status was 0 to 1 in 92 patients.
Thirty-five patients were refractory to the first cycle of chemother-
apy. Of them, 31 and 4 patients achieved CR and partial response,
respectively, upon the second cycle of induction chemotherapy.
According to the HOVON/SAKK (Swiss Group for Clinical Cancer
Research) risk classification (supplemental Appendix, details of the
HOVON 116 study, section 1), 77 patients were classified as very
poor risk. Transplant characteristics are depicted in Table 2. All
patients received 2 cycles of induction chemotherapy. The median
time from evaluation of the second cycle to allo-HSCT was 16 days
(range, 1-66), and the median time from diagnosis to allo-HSCT
was 110 days (range, 56-205). Forty-one patients received a graft
from a matched sibling donor, 61 from a fully matched unrelated
donor, and 8 from a mismatched unrelated donor. One patient
received a bone marrow graft from a sibling donor. The median
follow-up of patients who lived was 23 months. Sixty-seven patients
exhibited an EBMT (European Society for Blood and Marrow
Transplantation) score of $3 points.24
Part 1: feasibility of panobinostat alone and in
combination with decitabine
Analyses were performed on data from the first 10 patients in the
PNB mono and PNB/DAC10 groups. At interim analysis, 1 of 9
patients in the in PNB mono group experienced DLT. Four of 10
patients receiving PNB/DAC20 experienced DLT, consisting of
prolonged cytopenia. Consequently, PNB/DAC20 was not consid-
ered feasible. The combination of panobinostat and decitabine was
further evaluated in the PNB/DAC10 group (10 mg/m2 of decitabine).
Only 1 DLT was observed in the first 10 patients in the group, again
because of prolonged cytopenia. Subsequently, the study was
expanded, according to design, by inclusion of another 55 patients
in the PNB mono and PNB/DAC10 groups. Of note, in total, 13
patients were included in the PNB/DAC20 group because of
ongoing inclusion of patients during the interim analysis (Figure 1).
Part 2: completion of protocol treatment and
secondary end points
In the second part of the study, the completion of protocol treatment
up to the first DLI and outcome was evaluated. Eighty-seven of 110
patients who underwent transplantation were eligible for epigenetic
(Very) poor risk AML/RAEB with IPSS  1.5
18-70 years
After induction chemotherapy cycle I:
1. Start donor search for alloHSCT
2. Induction/consolidation
chemotherapy, Cycle II
Responsive
disease
(< 10% blasts after
cycle 2)
RIC-alloHSCT
cyclophosphamide
fludarabine
low dose TBI
2 cycles PNB/DAC q 28 days
panabinostat (20 mg on days 1, 4, 8, 11)
decitabine (0-20 mg/m2 i.v. on days 1-3/5
as indicated by dose level),
starting at post-transplant day +28
2 cycles PNB/DAC q 28 days
panabinostat (20 mg on days 1, 4, 8, 11)
decitabine (0-20 mg/m2 i.v. on days 1-3/5
as indicated by dose level),
starting at day 21 after DLI
First DLI: day +90-100
If no GVHD
Second DLI: day +180-200
If no GVHD
Third DLI
off protocol treatment
off protocol
treatment
no
yes
REGISTRATION
START
PROTOCOL
TREATMENT
Figure 1. Scheme of HOVON 116 study from registration to cessation of
protocol treatment. DAC, decitabine; IPSS, International Prognostic Scoring
System; PNB, panobinostat; RAEB, refractory anemia with excess blasts; RIC,
reduced-intensity conditioning.
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therapy and received the first cycle (Figure 1). The reasons for
withdrawal of the epigenetic drugs were GVHD (n 5 11),
thrombocytopenia (n 5 3), renal dysfunction (n 5 3), death (n 5
2), disease progression (n 5 2), liver dysfunction (n 5 1), and start
of the first cycle beyond day 35 after allo-HSCT (n 5 1). Of 110
patients who received allo-HSCT, 60 (55%) were eligible to receive
DLI within 115 days. In total, 63 of 75 (84%) patients who received
a second cycle of epigenetic therapy received their first planned
DLI. Second and third DLIs were given to 40 and 25 patients,
respectively. AEs considered to be related to panobinostat and
decitabine treatment are shown in Table 3. Epigenetic therapy–
related grade 3 and 4 AEs were observed in 23 (26%) of the 87
patients who received epigenetic therapy. Related hematological
AEs were noted in only 3 patients, consisting of 1 grade 2 and 2
grade 3 events. In general, panobinostat- and decitabine-related
AEs were rapidly reversible after treatment was interrupted. Of note,
AEs were not attributable to either panobinostat or decitabine when
the 2 were combined.
Figure 2 shows the CIR, NRM, PFS, and OS of all 110 patients who
underwent transplantation. The CIR at 24 months was 35% (SE 5),
and NRM at 24 months was 16% (SE 4). OS and PFS at 24 months
were 50% (SE 5) and 49% (SE 5), respectively. The cumulative
incidence of relapse at 24 months in the PNB mono group was
24% (SE 8), and the addition of decitabine did not improve the
outcome, with a CIR at 24 months of 46% (SE 9; P 5 .29) in the
PNB/DAC10 group (Figure 3). Although not significant, relapse
Table 1. Patient characteristics (N 5 110)
Characteristics n %
Age, y
Median 59
Range 18-71
Sex
Male 67 61
Female 43 39
WBC before SCT, 3109/L
Median 3.9
Range 0.10-19.5
WHO performance status
0 51 46
1 41 37
2 11 10
Unknown 7 6
Response to induction cycle 1
CR1Cri 66 61
PR 8 7
Refractory 35 32
Response to cycle 2
CR1Cri 105 96
PR 4 4
Blasts before SCT, %
Median 2
Range 0-10
MRD*
Positive 21 28
Negative 53 72
HOVON/SAKK risk group
Poor 33 30
Very poor 77 70
MK 15 19
EVI1 19 25
CR, complete remission; CRi, complete remission with incomplete hematologic recovery;
EVI1, ecotropic viral integration site 1; MK, monosomal karyotype; WBC, white blood cell
count; WHO, World Health Organization.
*By multiparameter flow cytometry in 74 patients.
Table 2. Transplant characteristics
Characteristics n %
Donor source
Sibling 41 37
Matched unrelated donor 61 55
Mismatched 8 7
Female donor to male recipient
No 90 82
Yes 20 18
Stem cell source
Peripheral blood 109 99
Bone marrow 1 1
PB CD341, 3106/kg
Median 6.4
Range 2-14
CMV serostatus patient/donor
Negative/negative 36 33
Positive/positive 33 30
Other 41 37
Time diagnosis to allo-HSCT, d
Median 110
Range 56-05
Time start CT2 to allo-HSCT, d
Median 62
Range 37-21
Time evaluation CT2 to allo-HSCT, d
Median 16
Range 1-66
Median follow-up for surviving patients, mo 23
EBMT risk score
0 2 2
1 4 3
2 35 32
3 59 54
4 8 7
Data are number of patients, percentage of the entire patient sample (N 5 110), unless
stated otherwise.
CMV, cytomegalovirus; CT, chemotherapy; EBMT, European Group of Blood and Marrow
Transplantation; PB, peripheral blood.
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was seen less often in MRD-negative than in MRD-positive patients
(CIR at 24 months 35% [SE 7] vs 43% [SE 11], respectively; P 5
.09; supplemental Figure 3). Outcome according to the HOVON
risk categories showed an OS of 63% (SE 10) and 46% (SE 6) at
24 months for poor- and very-poor-risk patients with AML,
respectively (supplemental Figure 2). As expected, ineligibility for
transplantation was associated with a dismal outcome; the overall
survival at 12 months was only 19% (SE 8) (supplemental Figure 4).
Acute GVHD grades 3 and 4 and grades 2 to 4 at 6 months were
seen in 5% (SE 2) and 23% (SE 4) of all patients, respectively, and
22% (SE 4) of the patients experienced moderate-to-severe
chronic GVHD at 12 months (Figure 4). Of the 110 patients who
underwent transplantation, survival was 36% (SE 5); none of the
patients experienced relapse or developed acute or chronic GVHD
requiring systemic therapy (supplemental Figure 5).
Discussion
Relapse after allo-HSCT remains the major cause of failure in
patients with AML.1 We showed earlier that allo-HSCT reduces
relapse in a similar relative degree in different subcategories of
Table 3. Number of AEs related to panobinostat and decitabine treatment
Epigenetic therapy–related toxicity
PNB mono (n 5 39), n (%) PNB/DAC20 (n 5 13), n (%) PNB/DAC10 (n 5 35), n (%)
G2 G3 G4 G2 G3 G4 G2 G3 G4
Blood and bone marrow 1 (2) 0 0 0 2 (13) 0 0 0 0
Gastrointestinal 2 (4) 2 (4) 0 0 0 0 3 (6) 1 (2) 1 (2)
Constitutional symptoms 2 (4) 1 (2) 0 1 (6) 0 0 0 0 0
Infections 3 (7) 0 0 0 0 0 0 0 1 (2)
Metabolic/laboratory 0 1 (2) 1 (2) 0 0 0 0 2 (4) 0
Eye 1 (2) 0 0 0 0 0 0 0 0
Nervous system 0 1 (2) 0 0 0 0 0 1 (2) 0
Skin and subcutaneous tissue 1 (2) 0 0 0 0 0 0 0 0
G, grade.
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Figure 2. Survival, relapse/progression and
NRM. Overall (OS) and progression-free survival
(PFS), relapse, and NRM Kaplan-Meier estimates of
OD (A), progression-free survival (B), CIR (C), and cu-
mulative incidence of NRM (D). F, number of failures.
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patients with AML.4,5 These findings provided evidence that
allogeneic GVL is present even in very-poor-risk patients with
AML, despite a higher absolute relapse rate after allo-HSCT. It
provided the rationale for exploit the GVL effect more deeply by
administering epigenetic therapy after allo-HSCT. Epigenetic
therapy was followed by DLI, to enhance the GVL effect, given
the poor antileukemic effect of panobinostat itself. In this study,
we showed that post–allo-HSCT epigenetic therapy with pan-
obinostat alone or in combination with decitabine is feasible in
terms of DLTs and AEs. From intent to treat up to the first DLI,
protocol treatment was administered to most patients within
a strict time frame of 115 days. Outcome with respect to disease
recurrence was promising, which may have been related to an
enhanced GVL effect.
Grade 3 and 4 AEs related to panobinostat and decitabine were
observed in 23 (21%) of the 87 patients who received epigenetic
therapy. AEs related to panobinostat and/or decitabine were
limited in our protocol, and hematological grade 3 and 4 disorders
were noted in only 4 patients. In general, these AEs were rapidly
reversible after epigenetic therapy was interrupted. In comparison,
in a prospective phase 1 trial, Pusic at al9 investigated post–allo-
HSCT decitabine treatment in patients with AML and reported
grade 3 to 4 hematological toxicities in 75% of the patients. The
difference may be explained, at least in part, by different dosages
and possible drug interactions caused by the combination of
GVHD-prophylaxis and post–allo-HSCT epigenetic therapy. Re-
cently, Bug et al12 explored panobinostat after allo-HSCT as
a maintenance therapy in poor-risk patients with AML. The applica-
tion of panobinostat after transplantation appeared to be feasible
with AEs related to panobinostat in 52% of the patients. In the
present study, the strategy of posttransplant cyclophosphamide
prophylaxis of GVHD, of which the feasibility and efficacy have been
demonstrated elaborately before,25-34 was applied in combination
with cyclosporine to enable effective GVHD prophylaxis and allow
for an early start of epigenetic therapy. Thereby, the majority of allo-
HSCT recipients (87 of 110; 79%) were eligible to start epigenetic
therapy. In addition, cyclophosphamide appeared to be associated
with limited acute and chronic GVHD and also limited NRM (16%)
at 24 months. These data compare well to those in previous studies
with post–allo-HSCT epigenetic therapy.6,7,9,12 Of note, in contrast
to Bug et al,12 only patients transplanted in CRi or PR were included
in the present study.
The early application of allo-HSCT in poor-risk patients with AML
has been stressed before by Schmid et al in refractory35 and more
recently in monosomal karyotype AML.36 Our study was designed
to apply allo-HSCT shortly after chemotherapy. To achieve this end,
patients were registered shortly after diagnosis, followed by a rapid
donor search. It resulted in a median time of 16 days (range, 1-66)
between evaluation after the second cycle of chemotherapy and
allo-HSCT. By study design, allo-HSCT was followed by epigenetic
therapy and DLI, preferably with the first DLI given by day 115 after
allo-HSCT. This rather ambitious schedule was successfully
achieved in 55% of patients. In previous studies exploring the
hypomethylating agents decitabine and azacitidine after allo-HSCT,
the percentage of patients actually receiving scheduled cycles
ranged between 20% and 43%, and treatment did not include
DLI.6-10 Moreover, none of these trials included patients before allo-
HSCT during chemotherapy and reported results by intent to treat.
By extending the feasible dose levels, we were able to study relapse
and compare relapse of patients in the PNB mono and PNB/DAC10
groups. No additive or synergistic effect of adding decitabine to
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Figure 3. CIR by feasible dose levels in the PNB mono and PNB/DAC10
groups. Kaplan-Meier estimates of CIR in both groups are shown.
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22 SEPTEMBER 2020 x VOLUME 4, NUMBER 18 PANOBINOSTAT AND DECITABINE PRIOR TO allo-HSCT 4435
D
ow
nloaded from
 http://ashpublications.org/bloodadvances/article-pdf/4/18/4430/1758388/advancesadv2020002074.pdf by guest on 26 O
ctober 2020
panobinostat was suggested. The cumulative incidence of relapse
at 24 months was 24% (SE 8) in recipients of panobinostat only,
whereas the CIR was 46% (SE 9, P 5 .29) after combination of
panobinostat and decitabine. Absence of a stronger GVL after
combination therapy may be explained by an antiproliferative effect
of decitabine on alloreactive T-cells, as decitabine exerts an
inhibitory effect on cell proliferation by blocking DNA-synthesis,
similar to, for example, cytarabine.37-40 Apart from its antiprolifer-
ative effects, decitabine may also exert an immunomodulatory effect
by increasing the number of Tregs through Foxp3 demethylation.41
Either of these mechanisms could jeopardize the allogeneic GVL
effect.
The results observed by Bug et al12 and us strongly warrant
a prospective comparison, which is currently ongoing. Bug et al12
reported a PFS of 75% at 24 months in allo-HSCT recipients
receiving panobinostat only, which is very encouraging and
compares well to our results. Of note, their study included patients
at a relatively late time point after allo-HSCT, leaving the possibility
of patient selection by excluding patients with early relapse and
those who had complications, again strongly suggesting a pro-
spective comparison, which the 2 study groups will cooperatively
perform. In addition, continuing preemptive therapy after allo-HSCT,
especially in very-poor-risk patients, could be considered, given that
there did not seem to be a plateau in the survival analyses. However,
toxicity and efficacy would have to be weighed and evaluated.
In summary, epigenetic therapy after allo-HSCT with panobinostat
alone and in combination with low-dose decitabine is feasible in
poor-risk AML and may be associated with enhanced GVL. Results
did not suggest a synergistic or additive effect of combining
panobinostat with decitabine. Our results and those of Bug et al12
have set the stage for the current European randomized intergroup
study, evaluating the efficacy of panobinostat in allo-HSCT
recipients with poor-risk patients with AML (ETAL-4/HOVON145;
ECT 2017-000764-15).
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